Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities:
Net loss	$ (37,371)	$ (40,817)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Provision for credit loss	1	53
Depreciation and amortization	4,982	3,993
Amortization-investment discount	(351)	0
Amortization-debt issuance costs	305	566
Amortization of payment-in-kind interest	0	1,070
Equity-based compensation	21,978	28,047
Non-cash lease expense	717	715
Changes in operating assets and liabilities:
Accounts receivable	(32,387)	(26,050)
Prepaid expenses and other current assets	(15,786)	(5,079)
Other assets	4	(167)
Medical expenses payable	15,535	29,077
Accounts payable and accrued expenses	(9,211)	(1,619)
Deferred premium revenue	140,773	(37)
Accrued compensation	(2,966)	(364)
Lease liabilities	(1,113)	(1,026)
Net cash provided by (used in) operating activities	85,110	(11,638)
Investing Activities:
Purchase of business, net of cash received	0	(1,113)
Purchase of investments	(104,243)	(850)
Sale of investments	1,100	750
Acquisition of property and equipment	(7,285)	(4,914)
Net cash used in investing activities	(110,428)	(6,127)
Financing Activities:
Contributions from noncontrolling interest holders	30	0
Net cash provided by financing activities	30	0
Net decrease in cash	(25,288)	(17,765)
Cash, cash equivalents and restricted cash at beginning of period	411,299	468,350
Cash, cash equivalents and restricted cash at end of period	386,011	450,585
Supplemental disclosure of cash flow information:
Cash paid for interest	4,277	2,758
Supplemental non-cash investing and financing activities:
Acquisition of property in accounts payable	10	331
Purchase of business in accounts payable	0	240
Reconciliation of cash, cash equivalents and restricted cash as shown in the statement of cash flows:
Cash and cash equivalents	384,261	448,835
Restricted cash in other assets	1,750	1,750
Total	$ 386,011	$ 450,585